The FDA and the EMA have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib for mCRPC.

Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, for C3-glomerulopathy (C3G).

PYC Therapeutics is set to begin Part B in its SAD study of the drug candidate, PYC-003, for polycystic kidney disease (PKD) patients.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.

The endometriosis market is expected to grow from $938.0m in 2024 to $2.5 billion in 2034, at a compound annual growth rate ...

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

Across 100 patients in three Phase III studies, Vertex's Casgevy showed lasting benefits for more than five years.

BioAtla has presented first-in-human Phase I study data of its anticancer therapy, BA3182, targeting those with metastatic adenocarcinoma.

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...

egnite has launched the CardioCare Research Suite, an advanced component of its flagship platform, aimed at enhancing patient identification processes for cardiovascular clinical trials. This tool is ...